fda approved glp-1 receptor agonists GI Adverse Effects of Glucagon-Like Peptide-1 FDA Approved: Orforglipron (Foundayo) —
Description
Future Developments in GLP-1 Research Scientists continue studying new applications for GLP-1 medications
There is no FDA-recognized microdose strategy for semaglutide, tirzepatide, or related medications

Multiple GLP-1 drugs linked to lower AFib risk GLP-1 receptor agonists (GLP-1-RAs) may be able to reduce a patient's risk of atrial fibrillation (AFib), according to new data presented at Heart Rhythm 2026 in Chicago
Because doses are lower, patients dont experience the severe appetite suppression that can unintentionally lead to muscle loss

EGD, esophagogastroduodenoscopy
